Friedemann Paul, MD, Charité-Universitätsmedizin Berlin, Berlin, Germany, discusses whether serum biomarkers, including sGFAP and sNfL, are helpful and should be used in NMOSD treatment monitoring. Studies investigating GFAP in the CSF have shown that GFAP levels increase during NMOSD attacks. These results have been recently replicated with serum, and a correlation was found between sGFAP and the risk of relapse. Additionally, the N-MOmentum study (NCT02200770) evaluating the efficacy of inebilizumab in NMOSD showed that sGFAP tends to peak around the time of an NMOSD attack, more so in patients receiving placebo, suggesting sGFAP might be a valuable biomarker for disease monitoring. In the future, this needs to be translated into an easily applicable diagnostic tool for individual patients. The use of sGFAP as a biomarker in NMOSD needs to be validated in larger cohorts, and investigators need to better understand how it correlates with disability and severity of attacks. This interview took place at the 17th World Congress on Controversies in Neurology (CONy) in Dubrovnik, Croatia.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Grants or contracts: German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Einstein Foundation, Guthy Jackson Charitable Foundation, EU FP7 Framework Program, Biogen, Genzyme, Merck Serono, Novartis, Bayer, Roche, Parexel and Almirall.
Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Guthy Jackson Foundation, Bayer, Biogen, Merck Serono, Sanofi Genzyme, Novartis, Alexion, Viela Bio, Roche, UCB, Mitsubishi Tanabe and Celgene.
Participation on a Data Safety Monitoring Board or Advisory Board: Celgene, Roche, UCB, Merck.
Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Academic Editor PLos One, Associate Editor von Neurology® Neuroimmunology & Neuroinflammation.